BobF, don't forget about R435, which is a variant of R327 aimed specifically at oral administration.
Source: https://finance.yahoo.com/news/recce-pharmaceuticals-announces-positive-oral-120000992.html
So, over four years ago, they split off oral dosage into a different development path, so that it will not interrupt development of the flagship product R327, which is aimed at IV administration targeting sepsis in the blood. That is it's primary goal.
They also created R529, for the same purpose; to not hold up development of R327, yet allow for specifically targeting viral infections.
Both variants as far as I understand, take a much lower priority to R327 and quite rightly so.
- Forums
- ASX - By Stock
- [INTERVIEW] Recce gearing up for Indonesian trials
BobF, don't forget about R435, which is a variant of R327 aimed...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RCE (ASX) to my watchlist
(20min delay)
|
|||||
Last
52.0¢ |
Change
0.005(0.97%) |
Mkt cap ! $120.5M |
Open | High | Low | Value | Volume |
54.0¢ | 54.0¢ | 52.0¢ | $4.485K | 8.497K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 17 | 52.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
53.0¢ | 14897 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 20282 | 0.515 |
1 | 290 | 0.510 |
1 | 50000 | 0.505 |
5 | 51000 | 0.500 |
1 | 6062 | 0.495 |
Price($) | Vol. | No. |
---|---|---|
0.530 | 14897 | 2 |
0.540 | 50460 | 5 |
0.545 | 12278 | 2 |
0.550 | 135601 | 3 |
0.560 | 5000 | 1 |
Last trade - 15.47pm 04/10/2024 (20 minute delay) ? |
Featured News
RCE (ASX) Chart |